Microlin Bio has filed plans to raise up to $25 million in an initial public offering designed to advance work on tests and related therapies for lung, ovarian, colorectal and prostate cancers. The New York startup was incorporated in July 2013. Microlin plans to trade on the Nasdaq under the symbol "MCLB." Story